Whereas NSG tumor-bearing mice (n = 7) treated with NKp30-CD137 CAR TCRKO T cells derived from BC 2 showed an initial anti-tumor response but progressed 10 days post T cell injection (Figure 6B,C), we observed a superior and long-lasting tumor immunity in the NKp30-CD28 CAR TCRKO T cell-treated group (n = 7). This evidence concerns the gene CD28 and breast cancer.